Literature DB >> 28094264

First-line therapy for mCRC - the influence of primary tumour location on the therapeutic algorithm.

Chiara Cremolini1, Carlotta Antoniotti1, Roberto Moretto1, Gianluca Masi1, Alfredo Falcone1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28094264     DOI： 10.1038/nrclinonc.2016.219

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  11 in total

1.  EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.

Authors:  Annika Ålgars; Jari Sundström; Minnamaija Lintunen; Terhi Jokilehto; Soili Kytölä; Milja Kaare; Reetta Vainionpää; Arto Orpana; Pia Österlund; Ari Ristimäki; Olli Carpen; Raija Ristamäki
Journal:  Int J Cancer       Date:  2016-11-23       Impact factor: 7.396

2.  Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.

Authors:  S Y Brulé; D J Jonker; C S Karapetis; C J O'Callaghan; M J Moore; R Wong; N C Tebbutt; Cr Underhill; D Yip; J R Zalcberg; D Tu; R A Goodwin
Journal:  Eur J Cancer       Date:  2015-05-12       Impact factor: 9.162

3.  The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.

Authors:  Julian Walter Holch; Ingrid Ricard; Sebastian Stintzing; Dominik Paul Modest; Volker Heinemann
Journal:  Eur J Cancer       Date:  2016-11-29       Impact factor: 9.162

4.  Primary tumor location as a prognostic factor in metastatic colorectal cancer.

Authors:  Fotios Loupakis; Dongyun Yang; Linda Yau; Shibao Feng; Chiara Cremolini; Wu Zhang; Martin K H Maus; Carlotta Antoniotti; Christiane Langer; Stefan J Scherer; Thomas Müller; Herbert I Hurwitz; Leonard Saltz; Alfredo Falcone; Heinz-Josef Lenz
Journal:  J Natl Cancer Inst       Date:  2015-02-24       Impact factor: 13.506

Review 5.  First-line chemotherapy for mCRC—a review and evidence-based algorithm.

Authors:  Chiara Cremolini; Marta Schirripa; Carlotta Antoniotti; Roberto Moretto; Lisa Salvatore; Gianluca Masi; Alfredo Falcone; Fotios Loupakis
Journal:  Nat Rev Clin Oncol       Date:  2015-07-28       Impact factor: 66.675

6.  Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features.

Authors:  E Missiaglia; B Jacobs; G D'Ario; A F Di Narzo; C Soneson; E Budinska; V Popovici; L Vecchione; S Gerster; P Yan; A D Roth; D Klingbiel; F T Bosman; M Delorenzi; S Tejpar
Journal:  Ann Oncol       Date:  2014-07-23       Impact factor: 32.976

7.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

Authors:  E Van Cutsem; A Cervantes; R Adam; A Sobrero; J H Van Krieken; D Aderka; E Aranda Aguilar; A Bardelli; A Benson; G Bodoky; F Ciardiello; A D'Hoore; E Diaz-Rubio; J-Y Douillard; M Ducreux; A Falcone; A Grothey; T Gruenberger; K Haustermans; V Heinemann; P Hoff; C-H Köhne; R Labianca; P Laurent-Puig; B Ma; T Maughan; K Muro; N Normanno; P Österlund; W J G Oyen; D Papamichael; G Pentheroudakis; P Pfeiffer; T J Price; C Punt; J Ricke; A Roth; R Salazar; W Scheithauer; H J Schmoll; J Tabernero; J Taïeb; S Tejpar; H Wasan; T Yoshino; A Zaanan; D Arnold
Journal:  Ann Oncol       Date:  2016-07-05       Impact factor: 32.976

8.  Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis.

Authors:  Fausto Petrelli; Gianluca Tomasello; Karen Borgonovo; Michele Ghidini; Luca Turati; Pierpaolo Dallera; Rodolfo Passalacqua; Giovanni Sgroi; Sandro Barni
Journal:  JAMA Oncol       Date:  2017-02-01       Impact factor: 31.777

9.  Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials.

Authors:  Sabine Tejpar; Sebastian Stintzing; Fortunato Ciardiello; Josep Tabernero; Eric Van Cutsem; Frank Beier; Regina Esser; Heinz-Josef Lenz; Volker Heinemann
Journal:  JAMA Oncol       Date:  2017-02-01       Impact factor: 31.777

10.  The consensus molecular subtypes of colorectal cancer.

Authors:  Justin Guinney; Rodrigo Dienstmann; Xin Wang; Aurélien de Reyniès; Andreas Schlicker; Charlotte Soneson; Laetitia Marisa; Paul Roepman; Gift Nyamundanda; Paolo Angelino; Brian M Bot; Jeffrey S Morris; Iris M Simon; Sarah Gerster; Evelyn Fessler; Felipe De Sousa E Melo; Edoardo Missiaglia; Hena Ramay; David Barras; Krisztian Homicsko; Dipen Maru; Ganiraju C Manyam; Bradley Broom; Valerie Boige; Beatriz Perez-Villamil; Ted Laderas; Ramon Salazar; Joe W Gray; Douglas Hanahan; Josep Tabernero; Rene Bernards; Stephen H Friend; Pierre Laurent-Puig; Jan Paul Medema; Anguraj Sadanandam; Lodewyk Wessels; Mauro Delorenzi; Scott Kopetz; Louis Vermeulen; Sabine Tejpar
Journal:  Nat Med       Date:  2015-10-12       Impact factor: 53.440
View more
  9 in total

Review 1.  Right Versus Left Colon Cancer: Resectable and Metastatic Disease.

Authors:  Michele Ghidini; Fausto Petrelli; Gianluca Tomasello
Journal:  Curr Treat Options Oncol       Date:  2018-05-23

2.  A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab.

Authors:  Martin D Berger; Sebastian Stintzing; Volker Heinemann; Shu Cao; Dongyun Yang; Yu Sunakawa; Satoshi Matsusaka; Yan Ning; Satoshi Okazaki; Yuji Miyamoto; Mitsukuni Suenaga; Marta Schirripa; Diana L Hanna; Shivani Soni; Alberto Puccini; Wu Zhang; Chiara Cremolini; Alfredo Falcone; Fotios Loupakis; Heinz-Josef Lenz
Journal:  Clin Cancer Res       Date:  2017-12-05       Impact factor: 12.531

3.  FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases.

Authors:  Carlotta Antoniotti; Guglielmo Vetere; Chiara Cremolini
Journal:  Ann Transl Med       Date:  2022-09

4.  Prognostic Impact of Primary Side and RAS/RAF Mutations in a Surgical Series of Colorectal Cancer with Peritoneal Metastases.

Authors:  Dario Baratti; Shigeki Kusamura; Monica Niger; Federica Perrone; Massimo Milione; Laura Cattaneo; Marcello Guaglio; Valentina Bartolini; Filippo Pietrantonio; Marcello Deraco
Journal:  Ann Surg Oncol       Date:  2020-09-24       Impact factor: 5.344

Review 5.  Non-Coding RNAs as Predictive Biomarkers to Current Treatment in Metastatic Colorectal Cancer.

Authors:  Ingrid Garajová; Manuela Ferracin; Elisa Porcellini; Andrea Palloni; Francesca Abbati; Guido Biasco; Giovanni Brandi
Journal:  Int J Mol Sci       Date:  2017-07-17       Impact factor: 5.923

6.  Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials.

Authors:  Xia-Hong You; Yu-Huan Jiang; Zhou Fang; Fan Sun; Yao Li; Wei Wang; Zi-Jin Xia; Xiao-Zhong Wang; Hou-Qun Ying
Journal:  ESMO Open       Date:  2020-03

7.  Utidelone inhibits growth of colorectal cancer cells through ROS/JNK signaling pathway.

Authors:  Fuli Li; Tinglei Huang; Yao Tang; Qingli Li; Jianzheng Wang; Xiaojiao Cheng; Wenhui Zhang; Baiwen Zhang; Cong Zhou; Shuiping Tu
Journal:  Cell Death Dis       Date:  2021-04-01       Impact factor: 8.469

Review 8.  Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective.

Authors:  Alberto Puccini; Andreas Seeber; Martin D Berger
Journal:  Cancers (Basel)       Date:  2022-10-03       Impact factor: 6.575

Review 9.  Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer.

Authors:  Fabio Catalano; Roberto Borea; Silvia Puglisi; Andrea Boutros; Annalice Gandini; Malvina Cremante; Valentino Martelli; Stefania Sciallero; Alberto Puccini
Journal:  Cancers (Basel)       Date:  2022-03-09       Impact factor: 6.639
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.